E-LIB Suche - Ergebnisse für: Ranti, Juha

1

Treatment and clinical outcomes of patients with acute myel..:

Ranti, Juha ; Pudas, Hanna ; Ranta, Martta...
European Journal of Haematology. , 2024

2

Prolonged viral pneumonia and high mortality in COVID-19 pa..:

Feuth, Eeva ; Nieminen, Valtteri ; Palomäki, Antti...
European Journal of Clinical Microbiology & Infectious Diseases. 43 (2024) 4 - p. 723-734 , 2024

Link: https://doi.org/10.1007/..

3

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WI..:

Kater, Arnon ; Dubois, Julie ; Brieghel, Christian...
HemaSphere. 7 (2023) S3 - p. e10648ed , 2023

Link: https://doi.org/10.1097/..

4

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATU..:

Urban, Aleksandra ; Hermansen, Johanne ; Yin, Yanping...
HemaSphere. 7 (2023) S3 - p. e92046ec , 2023

Link: https://doi.org/10.1097/..

5

Clinical and healthcare burden of disease associated with c..:

Ranti, Juha ; Perkonoja, Katariina ; Kauko, Tommi.
Transplant Infectious Disease. 24 (2022) 6 - p. , 2022

Link: https://doi.org/10.1111/..

6

Characterization of real‐world treatment practices and outc..:

Ranti, Juha ; Perkonoja, Katariina ; Kauko, Tommi...
eJHaem. 3 (2021) 1 - p. 291-300 , 2021

Link: https://doi.org/10.1002/..

7

Protocol description of the HOVON 141/VISION trial: a prosp..:

Levin, Mark-David ; Kater, Arnon ; Mattsson, Mattias...
BMJ Open. 10 (2020) 10 - p. e039168 , 2020

Link: https://doi.org/10.1136/..

8

Early CD8+-recovery independently predicts low probability ..:

Ranti, Juha ; Kurki, Samu ; Salmenniemi, Urpu...
PLOS ONE. 13 (2018) 9 - p. e0204136 , 2018

Link: https://doi.org/10.1371/..

9

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WI..:

Kater, Arnon ; Dubois, Julie ; Brieghel, Christian...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428369/. , 2023

Link: http://www.ncbi.nlm.nih...

10

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATU..:

Urban, Aleksandra ; Hermansen, Johanne ; Yin, Yanping...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428272/. , 2023

Link: http://www.ncbi.nlm.nih...

11

Clinical and healthcare burden of disease associated with c..:

Ranti, Juha ; Perkonoja, Katariina ; Kauko, Tommi.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369922/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Minimal residual disease-guided stop and start of venetocla..:

Kater, Arnon P ; Levin, Mark-David ; Dubois, Julie...
https://research.rug.nl/en/publications/97fc3009-72e0-4e71-8d6a-5ae4c749bac8. , 2022

Link: https://hdl.handle.net/1..

13

Characterization of real‐world treatment practices and outc..:

Ranti, Juha ; Perkonoja, Katariina ; Kauko, Tommi...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176063/. , 2021

Link: http://www.ncbi.nlm.nih...

14

Venetoclax and ibrutinib for patients with relapsed/refract..:

Niemann, Carsten U ; Levin, Mark David ; Dubois, Julie...
https://research.rug.nl/en/publications/98d01a12-fd30-4fee-916b-cdd713c9d5b3. , 2021

Link: https://hdl.handle.net/1..

15

Protocol description of the HOVON 141/VISION trial: a prosp..:

Levin, Mark-David ; Kater, Arnon ; Mattsson, Mattias...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566731/. , 2020

Link: http://www.ncbi.nlm.nih...